Log In
BCIQ
Print this Print this
 

EGF816

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionCovalent inhibitor of mutant-selective epidermal growth factor receptor
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/06/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today